Alle Studien
RekrutierungTherapeutische Bestätigung (Phase III)Interventionell

A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis

Generalised myasthenia gravis is a long-term condition that causes muscles to tire quickly and become weak. This can make everyday activities like walking, chewing, and speaking very tiring. This clinical trial is studying an injection called zilucoplan (brand name Zilbrysq) to see how well it works and how safe it is over a longer period. This is an 'open-label' study, which means there is no dummy drug (placebo). Everyone who takes part receives the active medicine using a pre-filled syringe. Doctors will track any side effects to make sure the medicine is safe. They will also test muscle strength and ask participants how the treatment affects their daily living and overall quality of life. The trial is open to adults aged 18 and older who have generalised myasthenia gravis.

Auf einen Blick

Status
Rekrutierung
Phase
Therapeutische Bestätigung (Phase III)
Sponsor
UCB Biopharma
Einschreibeziel
37
Starten
25 Jul 2024

Worum geht es in dieser Studie?

Generalised myasthenia gravis is a condition where the body's immune system mistakenly attacks the points where nerves connect to muscles. When these signals cannot get through properly, muscles become weak and tire very fast. Simple daily activities like smiling, lifting your arms, climbing stairs, or swallowing can become difficult and exhausting.

This trial is looking at a medicine called zilucoplan (brand name Zilbrysq). It works by blocking a specific part of the immune system that attacks the muscles. By calming this attack, doctors hope the medicine can help restore muscle strength and make everyday tasks easier. The medicine is given as an injection under the skin using a pre-filled syringe.

This is an 'open-label extension' study. In clinical trials, 'open-label' means that both you and your doctor know you are receiving the real treatment—no one receives a dummy drug (placebo). An 'extension' means the trial follows on from earlier studies to see how the medicine performs over a longer time. Researchers want to be certain that the treatment remains safe and continues to improve patients' quality of life.

Wichtige Erkenntnisse

  • Tests the long-term safety and benefits of zilucoplan (Zilbrysq) injections.
  • Designed for adults aged 18 and over with generalised myasthenia gravis.
  • This is an open-label trial, so there is no dummy drug (placebo).
  • Focuses on improving muscle strength and making daily tasks easier.
  • Participation is entirely voluntary and you can leave at any time.

Wer könnte berechtigt sein?

This study is for adults aged 18 and over who have been diagnosed with generalised myasthenia gravis. Both men and women may be able to join.

Because this is an extension study, it is generally intended for people who have already taken part in an earlier study of zilucoplan. Your study doctor will check if you meet all the health criteria to take part safely.

You might not be able to join if you have certain other serious illnesses, active infections, or if taking the study medicine is not considered safe for you. Your doctor will carefully review your medical history with you.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. I am aged 18 or older.
  2. I have a confirmed diagnosis of generalised myasthenia gravis.
  3. I have taken part in a qualifying earlier study for this medicine, or my doctor says I am eligible.
  4. I am able and willing to attend regular hospital appointments.
  5. I am comfortable giving myself an injection under the skin (or have a carer who can help).
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you take part, you will be given the study medicine, zilucoplan, as an injection under the skin. You or a carer will be shown how to use the pre-filled syringes at home. The exact dose you receive depends on your body weight.

You will need to attend regular clinic appointments so the medical team can check your health. During these visits, doctors will check your blood pressure, take blood samples, and ask about any side effects. They will also carry out simple physical tests to measure your muscle strength and ask you to fill in questionnaires about your daily life. A key check on your progress happens after 12 weeks of treatment, and your team will let you know how long your total study visits will continue.

Potenzielle Risiken und Vorteile

Taking part may help improve your muscle strength, relieve your symptoms, and make everyday tasks easier. However, there are also potential risks. Like all medicines, zilucoplan can cause side effects. Because it dampens part of your immune system, there could be a higher risk of infections, as well as mild redness or bruising where you inject the medicine. Your study team will watch you closely to keep you safe. Taking part is completely your choice, and you can leave the study at any time without giving a reason and without affecting your normal NHS care.

Standorte (4)

Einige Standortangaben sind ungefähr. Wir arbeiten daran, dies zu verbessern — bitte überprüfen Sie die Angaben mit dem Versuchsteam, bevor Sie reisen.
  • —
    Unbestätigt
    Norwegen
  • —
    Unbestätigt
    Polen
  • —
    Unbestätigt
    Spanien
  • —
    Unbestätigt
    Italien

Häufige Fragen

Will I receive a dummy drug (placebo)?

No. This is an open-label study, meaning every person who takes part receives the real study medicine.

How do I take the medicine?

The medicine is injected under the skin using a pre-filled syringe. The clinic staff will train you or a carer so you can do this comfortably at home.

Does it cost anything to take part?

No. The study medicine and all trial-related tests are provided free of charge, and travel expenses to hospital visits are often reimbursed.

Kann ich die Studie verlassen, wenn ich meine Meinung ändere?

Yes. You can leave the study at any time, for any reason. Your regular medical care will not be affected in any way.

How often will I need to see the doctor?

You will need to attend regular hospital visits, particularly in the first few months, so the team can monitor your safety and symptoms.

Wie Sie mehr erfahren können

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "A Phase 3, Multicenter, Open-Label Extension Study of Ziluco… wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.